ProCE Banner Activity

STAT: 48-Wk Results for a Rapid Test-and-Treat Approach Using DTG/3TC in Newly Diagnosed Adults With HIV

Slideset Download
Conference Coverage
Pilot study results support feasibility as first-line therapy in a test-and-treat setting, including in patients with a high HIV-1 RNA at baseline (ie, >500,000 copies/mL).

Released: October 03, 2021

Expiration: October 02, 2022

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Ferring Pharmaceuticals, Inc.

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp

ViiV Healthcare